Exacerbated Renal and Hematologic Toxicities to Ifosfamide and Doxorubicin-Based Chemotherapy in a Patient with Retroperitoneal Liposarcoma Harboring a Germline Mutation in the WRN Gene

Werner’s syndrome is caused by the inactivation of both WRN alleles and is characterized by premature aging and increased risk of neoplasms, especially those of mesenchymal origins, such as sarcomas. Given the characteristic genomic instability, patients with this syndrome are more susceptible to de...

Full description

Saved in:
Bibliographic Details
Published in:Case reports in oncology 2022-01, Vol.15 (1), p.170-175
Main Authors: Awni, Beatriz Mendes, Holanda Lopes, Carlos Diego, Harada, Guilherme, Salgues, Alessandra Corte Real, França, Gilmar de Andrade, Testagrossa, Leonardo de Abreu, Queiroz, Marcelo Araujo, Gonçalves e Silva, Adriano, Ferreira, Fabio de Oliveira, Munhoz, Rodrigo Ramella
Format: Article
Language:English
Subjects:
Anemia
Biopsy
Bone marrow
Case Report
Case reports
Chemotherapy
Collaboration
Creatinine
Cytotoxicity
DNA repair
Epidemiology
Gastric cancer
Genomes
hematological and renal toxicities
Hematology
Kidney diseases
Laboratories
Liposarcoma
Metabolism
Mutation
Patients
Proteins
Sarcoma
Tumors
werner’s syndrome
wrn
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Werner’s syndrome is caused by the inactivation of both WRN alleles and is characterized by premature aging and increased risk of neoplasms, especially those of mesenchymal origins, such as sarcomas. Given the characteristic genomic instability, patients with this syndrome are more susceptible to develop toxicities when exposed to cytotoxic agents, such as alkylators and anthracyclines. The impact of the monoallelic WRN mutation on treatment-associated toxicities is poorly understood. Here, we report a patient with locally advanced dedifferentiated liposarcoma of the retroperitoneum harboring a heterozygous germline inactivation mutation in the WRN gene, who was treated with a classic regimen of ifosfamide and doxorubicin and developed exacerbated and prolonged hematological and renal toxicities.
ISSN:1662-6575
1662-6575
DOI:10.1159/000521624